의약품 등급 유당 시장 - 예측(2026-2031년)

Pharmaceutical Grade Lactose Market is projected to increase at a 5.41% CAGR, growing from USD 2.006 billion in 2025 to USD 2.752 billion in 2031.

The global pharmaceutical-grade lactose market represents a specialized segment derived primarily from cheese production byproducts, adhering to rigorous quality standards for pharmaceutical applications. This high-purity lactose functions predominantly as an excipient-an inert substance serving as a vehicle for active pharmaceutical ingredients (APIs)-enhancing flowability, compressibility, stability, and taste in formulations. Key uses include tablet and capsule production, dry powder inhalers (DPIs), oral solutions, and as a diluent or filler in injectable and inhalable drugs. Additionally, pharmaceutical-grade lactose provides essential carbohydrates and energy in infant formulas, supporting early childhood nutrition and development. Rising awareness of its benefits in pediatric nutrition and pharmaceutical efficacy, coupled with escalating global healthcare expenditures, is propelling market expansion. The aging population and increasing prevalence of chronic diseases further amplify demand, as lactose facilitates oral solid dosage forms commonly prescribed for conditions like cancer, diabetes, and cardiovascular disorders.

Primary market drivers underscore structural healthcare trends. Growing investments in pharmaceutical manufacturing, particularly in emerging economies like India and Brazil, bolster production capacities for generics and novel therapies targeting chronic illnesses, directly elevating excipient requirements.

Rising chronic disease incidence, notably cancer-projected for a 70% increase in new cases over the next two decades-heightens demand for anticancer medications where lactose serves as a critical diluent and filler.

The versatility of pharmaceutical-grade lactose across applications-drug release modification, flavor masking, API stability enhancement, and improved solubility/bioavailability-positions it as a preferred excipient in diverse formulations.

Demographic shifts toward an older global population drive medication needs for age-related chronic conditions, with lactose integral to prevalent tablet and capsule formats.

From a segmentation perspective, the a-lactose monohydrate category is anticipated to dominate and exhibit substantial growth. Its widespread adoption as a filler, diluent, and carrier in solid dosage forms and DPIs stems from superior shelf-life extension compared to other lactose variants.

Geographically, North America is projected to maintain a significant market share and healthy CAGR. The region's leadership arises from a concentration of major producers and suppliers, alongside robust pharmaceutical industry growth in the United States-a leading global market for drug products. Increasing incorporation of lactose as an excipient in tablets, capsules, oral solutions, and inhalation powders supports demand. Furthermore, recognition of lactose-based infant formulas' digestive benefits and reduced gastrointestinal issues in infants is fostering formula uptake amid heightened parental and professional awareness.

Leading product offerings highlight specialized performance characteristics.

ARMOR PROTEINS' ARMOR PHARMA(TM) lactose monohydrate 200M is a finely milled a-lactose monohydrate powder optimized for wet and dry granulation in tablet production, delivering excellent mixing and compaction properties.

Charotar Casein Company's Lactose pharma undergoes meticulous processing to achieve low moisture (5.10%) and acidity (0.20), ensuring high purity, clarity, and efficacy under stringent quality controls.

BASF Corporation's Ludipress(R) is a co-processed granulate comprising lactose monohydrate (93%), Kollidon(R) 30 (3.5%), and Kollidon(R) CL (3.5%). This white, free-flowing, tasteless material simplifies tableting, yielding hard, low-friability tablets with rapid disintegration and API release.

The pharmaceutical-grade lactose market is underpinned by converging factors: chronic disease proliferation, geriatric demographics, excipient versatility, and pharmaceutical sector investments. North America's manufacturing ecosystem and formulation adoption reinforce its prominence, while a-lactose monohydrate's functional superiority drives segmental leadership. As global healthcare spending rises and awareness of lactose's role in drug delivery and infant nutrition grows, the sector presents sustained opportunities for suppliers focusing on purity compliance, customization, and application-specific innovations. Industry participants should monitor regulatory alignments and emerging therapies to optimize positioning in this resilient excipient category.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Pharmaceutical Grade Lactose Market Segmentation

• By Product Type
• B-lactose
• a-Lactose monohydrate
• Amorphous Lactose
• Spray Dried Lactose
• By Application
• Tablets
• Capsules
• Dry Powder Inhalers (DPI)
• Sachets
• Parenteral Formulations (Bulking Agent)
• Oral Suspensions
• By End-User
• Pharmaceutical Companies
• Contract Manufacturing Organizations (CMOs)
• Contract Development & Manufacturing Organizations (CDMOs)
• Nutraceutical Manufacturers
• Research & Development Laboratories
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PHARMACEUTICAL GRADE LACTOSE MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. B-lactose
• 5.3. a-Lactose monohydrate
• 5.4. Amorphous Lactose
• 5.5. Spray Dried Lactose

6. PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Tablets
• 6.3. Capsules
• 6.4. Dry Powder Inhalers (DPI)
• 6.5. Sachets
• 6.6. Parenteral Formulations (Bulking Agent)
• 6.7. Oral Suspensions

7. PHARMACEUTICAL GRADE LACTOSE MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical Companies
• 7.3. Contract Manufacturing Organizations (CMOs)
• 7.4. Contract Development & Manufacturing Organizations (CDMOs)
• 7.5. Nutraceutical Manufacturers
• 7.6. Research & Development Laboratories

8. PHARMACEUTICAL GRADE LACTOSE MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Indonesia
  • 8.6.7. Thailand
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Armor Proteines (Savencia Group)
• 10.2. BASF Corporation
• 10.3. Charotar Casein Company
• 10.4. Fengchen Group Co., Ltd.
• 10.5. Alpavit
• 10.6. Kavya Pharma
• 10.7. Lactose (India) Limited
• 10.8. MEGGLE GmbH & Co. KG
• 10.9. FrieslandCampina
• 10.10. Surfachem Group Ltd. (2M Holdings).

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations